content top

3 Cases of MH Following Intravitreal Injection with Ranibizumab

Poster Youngduk Kim Purpose: To report three cases of macular hole formation in patients who was administered intravitreal ranibizumab. Method: The first case was a 72-year-old man with age related macular degeneration and vitreomacular adhesion. The second case was a 76-year-old woman with subretinal haemorrhage and high PED. She was diagnosed with ARMD. The third case was 51-year-old woman with subretinal haemorrhage and high myopia....

Read More

Intravitreal Ranibizumab for Best’s Vitelliform Macular Dystrophy in a 38 Year-old Asian Woman

Advantages: To describe the effect of intravitreal ranibizumab for the treatment of choroidal neovascularisation and macular edema secondary to Best’s vitelliform macular dystrophy. Methods: A 38-year-old Asian woman with confirmed Best’s disease presented with decreased visual acuity (VA) due to secondary choroidal neovascularisation and macular edema. She was treated with a single intravitreal injection of ranibizumab (Lucentis, 0.5...

Read More

9 Months Results of Intravitreal Bevacizumab Injection for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

http://www.evrs.eu/medias/2009/congress/Retinal-Vein-Occlusions.flv Authors: Sun-Taek Lim, Chang-Ryong Kim, Young-Duk Kim, South Korea Background: To evaluate the long-term functional and anatomical effectiveness of intravitreal bevacizumab treatment in eyes with macular edema due to branch retinal vein occlusion (BRVO). Methods: In this retrospective interventional case series, 59 consecutive, previously untreated eyes with macular edema...

Read More

Direct Tissue Plasminogen Activator Infusion Into a Branch Retinal Vein in Patients with Central Retinal Vein Occlusion

Sun-Taek Lim, (Gwangju, South Korea), Young-Duk Kim, MD, PhD (Gwangju, Korea), Chang-Ryong Kim, MD, PhD (Gwangju, Korea), Yeon Lee, MD, PhD (Gwangju, Korea) PURPOSE: To evaluate visual acuity outcomes and retinal blood circulation after direct tissue plasminogen activator (t-PA) infusion into a branch retinal vein. METHODS: In this prospective, non-comparative, casecontrol study, ten eyes of ten consecutive patients with central retinal...

Read More
content top